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  Abstract	  Cells	  employ	  autophagy	  to	  recycle	  unneeded	  or	  damaged	  material	  and	  this	  process	  is	   crucial	   to	   keep	   cellular	   homeostasis.	   Consequently,	   excessive	   or	   insufficient	  autophagy	   levels	   can	   be	   deleterious	   for	   the	   cells	   and	   are	   strongly	   related	   with	  diseases	   such	   as	   cancer	   and	   neurodegenerative	   disorders,	   respectively.	   	   Many	  efforts	  have	  been	  done	  in	  the	   last	  decade	  to	  elucidate	  the	  mechanisms	  regulating	  autophagy.	   These	   studies	   have	   enabled	   the	   in-­‐depth	   characterization	   of	   new	  targets	   that	   have	   been	   employed	   to	   design	   and	   identify	   novel	   autophagy	  modulators	   of	   great	   interest	   as	   potential	   therapeutic	   agents.	   In	   this	   report	   an	  overview	  will	  be	  given	  of	  the	  different	  autophagy-­‐related	  targets	  as	  well	  as	  of	  the	  compound	  classes	  that	  have	  been	  identified,	  designed	  and	  synthesized	  to	  modulate	  this	  cellular	  process.	  	  
Introduction	  	  Autophagy	   (or	   self-­‐eating)	   is	   a	   cellular	   pathway	   that	   regulates	   the	   lysosomal	  degradation	   and	   recycling	   of	   obsolete	   organelles,	   long-­‐lived	   proteins,	   protein	  aggregates	  and	  pathogens.	  This	  process	  occurs	  under	  basal	   conditions	  and	  has	  a	  crucial	  role	  in	  cellular	  development,	  differentiation,	  survival	  and	  homeostasis.1	  	  Three	   different	   pathways	   can	   be	   used	   for	   this	   purpose:	   the	   chaperone-­‐mediated	  autophagy	   (CMA),	   microautophagy	   and	   macroautophagy.	   In	   the	   chaperone-­‐mediated	  autophagy,	  cytosolic	  proteins	  to	  be	  degraded	  are	  specifically	  selected	  by	  chaperones	   such	   as	   Hsc70	   that	   recognize	   a	   pentapeptide	   in	   their	   sequence	  (KFERQ-­‐like)	  and	  by	  doing	  so	  target	  them	  to	  the	  lysosomal	  membrane	  where	  they	  will	   interact	   with	   proteins	   such	   as	   LAMP2	   (lysosome-­‐associated	   membrane	  protein	   type	   2A).	   After	   getting	   unfolded,	   proteins	   will	   get	   internalized	   in	   the	  lysosome	  and	  subsequently	  degraded	  by	  lysosomal	  hydrolases	  (Figure	  1).	  The	  less	  investigated	   microautophagy	   relies	   on	   the	   direct	   invagination	   of	   the	   lysosomal	  membrane	   to	   engulf	   cytosolic	   cargos.	   Finally,	   macroautophagy,	   also	   known	   as	  autophagy,	   is	   the	   best	   characterized	   pathway.2	   This	  mechanism	   is	   initiated	  with	  the	   formation	  of	   a	   phagophore,	   a	   cup-­‐shaped	  double	  membrane	   that	   engulfs	   the	  cytoplasmic	  material	  to	  be	  degraded.	  The	  phagophore	  is	  then	  elongated	  and	  sealed	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to	  generate	  an	  autophagosome	  that	  will	  fuse	  with	  the	  lysosome,	  thereby	  delivering	  the	  cargo	  for	  its	  degradation	  (Figure	  1).	  	  	  Autophagy	  is	  involved	  in	  several	  essential	  cellular	  processes.	  As	  example,	  it	  has	  a	  key	   role	  under	   starving	   conditions	  by	  enabling	   the	   recycling	  of	   cellular	  proteins,	  lipids	   or	   carbohydrates.	   Moreover,	   it	   also	   prevents	   pathogen	   infection	   and	  participates	   in	   the	   elimination	   of	   protein	   aggregates	   and	   in	   the	   clearance	   of	  misfolded	  and	  ubiquinated	  proteins	  and	  damaged	  organelles.	  Due	  to	  this	  essential	  role	   in	   cellular	   homeostasis,	   excessive	   or	   deficient	   levels	   of	   autophagy	   are	  responsible	   for	   several	   pathologies	   and	   are	   strongly	   associated	   with	   aging	  processes.3	   Briefly,	   down-­‐regulation	   of	   autophagy	   impairs	   the	   clearance	   of	  aggregated	   proteins	   and	   is	   correlated	   with	   the	   progress	   of	   neurodegenerative	  diseases	  such	  as	  Parkinson,	  Alzheimer	  or	  the	  Huntington	  disease.4	  Similarly,	  aging	  processes	   are	   characterized	   by	   deficient	   levels	   of	   autophagy	   and	   consequently	  lifespan	   extension	   and	   longevity	   are	   clearly	   linked	   to	   the	   capacity	   of	   accurately	  regulate	   autophagy.3	   Dysfunction	   of	   this	   pathway	   has	   also	   been	   related	   with	  cancer.	   In	   the	   early	   stages	   of	   tumorigenesis	   autophagy	   seems	   to	   function	   as	   an	  alternative	  apoptotic	  pathway	  inducing	  the	  death	  of	  certain	  cells.5	  However,	  upon	  chemotherapy	  or	  radiotherapy	  cancer	  cells	  may	  induce	  protective	  autophagy	  as	  a	  way	  to	  escape	  from	  the	  stress	  and	  hypoxia	  conditions	  caused	  by	  the	  treatment	  and	  ultimately	   to	   acquire	   resistance	   and	   capacity	   for	   survival.	   Hence,	   due	   to	   the	  implication	  of	  autophagy	  in	  these	  relevant	  diseases,	  the	  identification	  of	  chemical	  modulators	  that	  can	  regulate	  autophagy	  either	  positively	  or	  negatively	  has	  became	  an	  emerging	  area	  of	  research.5,	  6	  Autophagy	  inducers	  are	  seen	  with	  great	   interest	  for	   the	   development	   of	   novel	   therapeutic	   strategies	   for	   the	   treatment	   of	  neurodegenerative	   diseases	   and	   as	   longevity	   agents,	   that	   is	   compounds	   able	   to	  extent	   the	   expected	   lifespan.6	   On	   the	   contrary,	   autophagy	   inhibitors	   may	   be	  employed	  in	  diseases	  characterized	  with	  excessive	  levels	  of	  cellular	  autophagy	  as	  is	  the	  case	  of	  several	  types	  of	  cancers,	  particularly	  the	  ones	  resistant	  to	  treatment.7,	  8	   The	   combination	   of	   chemotherapy	   and	   autophagy	   inhibitors	   have	   already	  showed	   promising	   results	   in	   the	   treatment	   of	   several	   types	   of	   cancers,	   thus	  confirming	  this	  hypothesis.7	  	  An	   important	   point	   in	   order	   to	   develop	   new	   autophagy	   modulators	   is	   to	  understand	   in	   more	   detail	   the	   mechanism	   that	   regulates	   this	   process.	   Cellular	  autophagy	   is	   a	   complex	   process	   that	   involves	   many	   signalling	   pathways	   and	  consequently	   it	   can	   be	   regulated	   at	  multiple	   stages	   (Figure	   1).	   The	   first	   step	   in	  autophagy	  is	  the	  formation	  of	  the	  initial	  phagophore	  that	  starts	  with	  the	  nucleation	  of	  a	  specific	  membrane	  and	  the	  sequestration	  of	   the	  cargo	  to	  be	  degraded.	  There	  are	  many	  pathways	  that	  regulate	  this	  initial	  step.	  The	  classic	  regulating	  pathway	  is	  the	   mTOR	   (mammalian	   target	   of	   rapamycin)-­‐signalling	   pathway	   although	   other	  signalling	  cascades	  independent	  of	  mTOR	  have	  also	  been	  described.	  	  The	   mTOR	   pathway	   is	   a	   signalling	   network	   that	   connects	   extracellular	   and	  intracellular	   signals	   to	   adapt	   the	   cellular	   metabolism	   to	   nutrient	   fluctuations.	  Under	   nutrient	   rich	   conditions	   or	   in	   the	   presence	   of	   insulin,	   this	   pathway	   is	  activated	   (and	   autophagy	   inhibited)	   to	   promote	   anabolic	   cell	   growth.	   Contrarily,	  the	  depletion	  of	  nutrients	  or	  growth	  factors	  leads	  to	  a	  decrease	  in	  its	  activity.	  As	  a	  consequence,	   cells	   initiate	   autophagy,	   that	   is	   the	   breakdown	   and	   recycle	   of	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unnecessary	   proteins	   or	   cellular	   components,	   with	   the	   aim	   to	   keep	   cellular	  homeostasis.	   The	   key	   role	   of	   mTOR	   pathway	   in	   autophagy	   regulation	   has	   been	  proven	  by	  the	  induction	  of	  lifespan	  extension	  upon	  genetic	  and	  chemical	  inhibition	  of	   mTOR-­‐signalling.9,	   10	   Other	   key	   regulators	   of	   autophagy	   do	   not	   involve	   the	  mTOR	  network.	  Hence,	  modulation	  of	  the	  cellular	  calcium	  content	  or	  of	  the	  inositol	  1,4,5-­‐triphosphate	  (IP3)	  levels	  can	  also	  regulate	  autophagy	  in	  a	  mTOR-­‐independent	  manner	  (Figure	  1).	  After	  the	  initial	  formation	  of	  the	  phagophore,	  depending	  or	  not	  on	  mTOR	  activity,	  the	  phagophore	  is	  then	  elongated	  and	  closes	  to	  form	  the	  autophagosome.	  The	  final	  step	   is	   the	   fusion	  of	   the	   resulting	  autophagosome	  with	   the	   lysosome,	   forming	  an	  autophagolysosome,	   and	   the	   enzymatic	   digestion	   of	   autophagosome	   cargo	   by	  lysosomal	  hydrolases.	  As	   a	   result	   of	   the	   crucial	   role	   of	   the	   mTOR-­‐signalling	   pathway	   in	   the	   negative	  regulation	  of	  autophagy,	  most	  of	   the	  currently	  known	  autophagy	   inducers	  act	  by	  blocking	  members	  of	  this	  signalling	  cascade.	  Moreover,	  other	  autophagy	  inducers	  that	   act	   by	   lowering	   IP3	   levels	   or	   by	   decreasing	   cytosolic	   calcium	   content	   have	  been	   also	   described.	   Some	   autophagy	   inhibitors	   have	   been	   also	   reported.	   This	  category	  includes	  kinase	  inhibitors	  blocking	  the	  activity	  of	  phosphatidylinositol	  3-­‐kinases	   	  (PI3K),	  compounds	  targeting	  directly	  or	  indirectly	   lysosomal	  hydrolases,	  and	  inhibitors	  of	  the	  lysosomal	  fusion	  with	  the	  autophagosome.	  In	  this	  review,	  an	  overview	  will	  be	  given	  on	  the	  autophagy	  modulators	  described	  up	  to	  now	  with	  the	  main	  purpose	  of	  giving	  the	  chemists	  interested	  in	  this	  research	  field	   a	   broad	   overview	   on	   the	   existing	   autophagy	   modulators	   and	   the	   methods	  employed	   for	   their	   identification.	   Most	   of	   the	   methods	   employed	   to	   monitor	  autophagy	   rely	   on	   the	   detection	   of	   the	   lipidated	   autophagy	   marker	   LC3-­‐II	  (MAP1LC3,	   Microtubule-­‐associated	   proteins	   1A/1B	   light	   chain	   3,	   see	   below)	  employing	   antibodies	   recognizing	  both	   the	  non-­‐lipidated	  LC3-­‐I	   as	  well	   as	   LC3-­‐II.	  Fluorescence	  microscopy	  approaches	  using	  various	  labelled	  proteins	  (GFP-­‐LC3	  or	  mRFP-­‐LC3-­‐eGFP)	   or	   electron	   microscopy	   methods	   have	   been	   also	   widely	   used.	  	  Since	  the	  methods	  employed	  to	  assess	  autophagy	  will	  not	  be	  described	  in	  detail	  in	  this	   revision	   article,	   for	   a	   complete	   overview	   on	   the	   existing	   assays	   to	   monitor	  changes	  in	  autophagy	  levels,	  the	  reader	  is	  referred	  to	  an	  excellent	  review	  covering	  all	  the	  described	  methods.11	  	  The	  compounds	  will	  be	  initially	  divided	  depending	  on	  their	  activity	  as	  autophagy	  inducers	  or	  inhibitors.	  In	  each	  category,	  the	  described	  modulators	  will	  be	  classified	  according	  to	  their	  target	  and	  compound	  classes.	  Some	  of	  the	  included	  compounds	  have	   been	   identified	   after	   high-­‐throughput	   screening	   (HTS)	   assays	   employing	  compound	   libraries.	   In	   some	  other	   cases,	   a	   rational	  design	  based	  on	  activity	  and	  structural	  information	  has	  been	  employed.	  For	  the	  most	  relevant	  modulators,	  the	  synthetic	  methods	  employed	  to	  obtain	  these	  compounds	  as	  well	  as	  their	  selectivity	  profile	   and	   the	   factors	   involved	  on	   their	  design	  will	   be	  described	   in	  more	  detail.	  Moreover,	   since	   the	   biological	   activity	   and	   selectivity	   profile	   of	   the	   chemical	  modulators	   will	   be	   also	   reported,	   we	   expect	   that	   this	   revision	   article	   may	   also	  serve	   as	   starting	  point	   for	   choosing	  of	   control	   substances	   in	  biological	   assays	   or	  drug	  discovery	  processes.	  	  





Figure	  1.	  Signalling	  pathways	  involved	  in	  autophagy	  (Macroautophagy	  and	  Chaperone-­‐mediated	  autophagy)	  regulation	  including	  the	  described	  inhibitors	  (in	  green	  squares)	  and	  inducers	  (in	  blue	  squares).	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AUTOPHAGY	  INDUCERS	  
	  
mTOR-­‐dependent	  pathway	  The	   best	   characterized	   regulator	   of	   autophagy	   is	   nutrient	   availability.	  Consequently,	   the	   classical	   and	   most	   important	   pathway	   involved	   in	   autophagy	  regulation	   is	   the	   mTOR	   pathway.12	   This	   pathway	   has	   a	   crucial	   role	   in	   the	  regulation	  of	  protein	  synthesis,	  cell	  growth	  and	  proliferation.	  The	  central	  molecule	  of	   this	   signalling	   network	   is	   the	   protein	   kinase	  mTOR,	   after	  which	   the	   complete	  pathway	  is	  named.	  When	  nutrients	  are	  abundant,	  mTORC1	  phosphorylates	  ULK-­‐1	  and	  by	  doing	  so	  blocks	  autophagy	  initiation,	  whereas	  when	  nutrients	  are	  limited,	  mTORC1	  dissociates	  from	  the	  ULK1	  complex	  and	  initiates	  the	  autophagy	  process.	  Inhibition	   of	   mTOR	   pathway	   by	   directly	   acting	   on	   the	   mTOR	   kinase	   or	   on	  downstream	  kinases	  such	  as	  PI3K,	  AMPK	  (AMP-­‐activated	  protein	  kinase)	  or	  AKT	  has	   been	   widely	   investigated	   for	   the	   search	   of	   autophagy	   inducers	   and	   will	   be	  described	  below.	  Most	  of	   the	  compounds	  belonging	  to	  this	  section	  are	  protein	  or	  lipid	  kinase	  inhibitors.	  	  
Rapamycin	  and	  rapalogues	  Rapamycin	  was	  first	  isolated	  in	  1975	  from	  a	  soil	  sample.	  This	  macrolide	  produced	  by	  Streptomyces	  hygroscopius	  was	  originally	  classified	  as	  antifungal	  agent	  and	   its	  name	   derives	   from	   its	   origin	   in	   the	   Easter	   Island,	   known	   locally	   as	   Rapa	   Nui.13	  Rapamycin	   (also	   known	   as	   sirolimus,	   Pfizer/Wyeth)	   is	   used	   as	  immunosuppressant	   in	   the	   prevention	   of	   transplant	   rejection.	   Moreover,	  rapamycin	   synthetic	   derivatives	   (rapalogues)	   with	   reduced	   immunosuppressive	  effects	   and	   improved	   pharmacokinetic	   properties,	   such	   as	   everolimus	   (RAD001,	  Novartis),	  the	  water	  soluble	  prodrug	  temsirolimus	  (CCI-­‐779,	  Wyeth),	  zotarolimus	  (ABT-­‐578)	  and	  ridaforolimus,	  formerly	  known	  as	  deforolimus	  (AP-­‐23573,	  Merck),	  have	  been	  developed.14	  Although	  the	  rapalogues	  were	  mainly	  designed	  for	  cancer	  treatment	  they	  have	  also	  shown	  their	  potential	  use	  as	  anti-­‐aging	  agents10	  (Figure	  2).	  	  A	   key	   breakthrough	   in	   rapamycin	   research	  was	   the	   identification	   of	   its	  mode	   of	  action	   and	   target.	   Rapamycin	   binds	   and	   inhibits	   mTOR	   	   (mammalian	   target	   of	  rapamycin)	   that	   was	   named	   as	   a	   result	   of	   this	   discovery.	   More	   specifically,	  rapamycin	  binds	  the	  peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP12	  and	  the	  resulting	  complex	   binds	   to	   the	   FRB	   domain	   (FKBP12–rapamycin-­‐binding)	   of	   mTOR	   that	  results	   in	   mTOR	   allosteric	   inhibition.15	   FKB12	   can	   not	   bind	   the	   FRB	   domain	   of	  mTOR	  in	  absence	  of	  rapamycin,	  thus	  rapamycin	  acts	  as	  protein-­‐protein	  interaction	  stabilizing	   agent	   that	   mediates	   the	   formation	   of	   a	   ternary	   complex.16	   The	   high	  affinity	  of	  rapamycin	  for	  FKBP12	  (Kd=	  0.2	  nM)	  and	  FRB	  relies	  on	  a	  number	  of	  key	  hydrogen	  bonds	  involving	  the	  pipecolic	  acid	  region,	  the	  tricarbonyl	  region	  from	  C-­‐8	   to	   C-­‐10,	   and	   the	   lactone	   functionalities.	   The	   triene	   region	   (C16-­‐to	   C-­‐23)	   of	  rapamycin	  also	  present	  important	  hydrophobic	  contacts	  with	  aromatic	  residues	  in	  the	  FRB	  domain	  (Figure	  2).17	  mTOR	   is	   present	   in	   two	   different	   protein	   complexes:	   mTORC1	   that	   regulates	  protein	  synthesis,	  cell	  growth	  and	  proliferation	  after	  sensing	  of	  nutrients,	  growth	  factors	  and	  energy,	  and	  mTORC2	  that	  promotes	  cellular	  survival	  by	  activating	  AKT,	  upstream	   of	   mTOR	   (Figure	   1).	   Activated	   AKT	   can	   in	   turn	   activate	   mTORC1	   in	  
	   6	  
which	  is	  known	  as	  a	  feedback	  loop.	  Since	  Rapamycin	  affects	  only	  mTORC1	  activity,	  these	   derivatives	   are	   not	   able	   to	   block	   the	   feedback	   loop	   involving	   AKT	   and	  consequently	  they	  present	  insufficient	  clinical	  efficiency.	  	  	  
	  
Figure	  2.	  X-­‐ray	  co-­‐crystal	  structure	  of	  the	  ternary	  complex	  formed	  by	  FKBP12,	  the	  FRB	   domain	   of	  mTOR	   and	   rapamycin.	   Chemical	   structure	   of	   rapamycin	   and	   the	  rapalogues	  highlighting	  the	  FKBP12	  and	  FRB-­‐binding	  regions.	  Inhibition	  of	  mTOR	  causes	  an	  autophagy	  response	  that	   is	  comparable	  to	  nutrient	  starvation. Thus,	  Rapamycin	  (10	  to	  500	  nM)	  and	  amino	  acid	  deprivation	  are	  still	  widely	   used	   as	   positive	   control	   method	   in	   basic	   research	   to	   induce	   autophagy.	  However,	  Rapamycin	  effects	  as	  autophagy	  inducer	  may	  be	  slow,	  transient	  and	  cell-­‐specific	  (a	  weaker	  effect	  has	  been	  observed	  on	  neurons	  compared	  to	  non-­‐neuronal	  cells).18	  As	  a	  result,	  specific	  mTOR	  inhibitors	  that	  target	  the	  ATP	  binding	  site	  of	  the	  serine/threonine	  (Ser/Thr)	  kinase	  mTOR	  and	  the	  lipid	  kinase	  PI3K	  have	  emerged	  in	   the	   last	   years	   and	  have	   shown	   to	  be	  more	  potent	   inducers	   of	   autophagy	   than	  Rapamycin.	  Some	  of	  the	  most	  representative	  examples	  of	  this	  inhibitor	  classes,	  PI-­‐103,	   BEZ235,	   PP242,	   Torin,	   Ku0063794,	   as	   well	   as	   their	   synthesis,	   will	   be	  described	  in	  detail	  below.	  Kinases	  	  are	  the	  major	  regulators	  and	  transducers	  of	  signalling	  in	  eukaryotic	  cells.	  These	   enzymes	   transfer	   phosphate	   from	   adenosine	   triphosphate	   (ATP)	   to	   their	  substrates,	   which	   can	   be	   proteins	   to	   be	   phosphorylated	   at	   serine,	   threonine,	  tyrosine	   or	   histidine	   residues	   or	   lipids,	   such	   as	   phosphatidylinositol	   (PI),	   which	  can	  be	  phosphorylated	  at	  one	  or	  more	  hydroxyls	  at	  the	  inositol	  ring.	  Protein	  kinase	  is	  one	  of	  the	  largest	  enzyme	  families	  and	  comprises	  more	  than	  500	  members	  that	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share	   high	   similarities	   at	   the	   catalytic	   kinase	   domain	   and	   the	   ATP	   binding	   site.	  Consequently,	  the	  search	  for	  selective	  kinase	  inhibitors	  targeting	  the	  ATP	  binding	  site	  of	  a	  particular	  kinase	  without	  affecting	  many	  other	  kinases	  has	  been	  a	  major	  challenge	  in	  research.	  In	  the	  last	  decade,	  several	  advances	  in	  structural	  biology	  and	  novel	  medicinal	   chemistry	   approaches	   have	   enabled	   the	   synthesis	   of	   potent	   and	  selective	   kinase	   inhibitors.	   Most	   of	   the	   identified	   kinase	   inhibitors	   are	   ATP-­‐competitive.	   These	   compounds	   usually	   contain	   a	   heterocycle	   that	   mimics	   the	  hydrogen	  bonds	   formed	  by	   the	  adenine	   ring	  of	  ATP	  with	   residues	   located	  at	   the	  ATP-­‐binding	   site	   and	   different	   substitution	   patterns	   directed	   to	   fill	   the	  hydrophobic	  pockets	  present	  in	  the	  binding	  site.19	  
Dual	  PI3K	  class	  I	  and	  mTOR	  inhibitors	  
	  The	   alternative	   AKT	   activation	   seen	   with	   rapamycin	   and	   the	   rapalogues	   made	  necessary	   alternative	   strategies	   blocking	   also	   this	   feedback	   loop.	   This	   led	   to	   the	  development	   of	   multitargeting	   compounds	   that	   simultaneously	   inhibit	   two	   or	  more	  proteins	  in	  the	  PI3K/AKT/mTOR	  pathway.	  Although	  mTOR	  is	  a	  Ser/Thr	  kinase,	  it	  is	  closely	  related	  to	  the	  family	  of	   	  the	  lipid	  kinase	   PI3K.	   The	   similarity	   in	   the	   catalytic	   domains	   of	   mTOR	   and	   PI3K	   have	  facilitated	   the	  search	   for	   inhibitors	  able	   to	  simultaneously	  block	   the	  ATP	  binding	  sites	  of	  both	  mTOR	  and	  PI3K	  kinases.	  In	  mammalian	  cells,	  PI3K	  have	  been	  divided	  in	   three	  classes	   (class	   I,	   II	  and	   III)	  on	   the	  basis	  of	   its	   lipid	  substrate	  specificity.20	  The	   class	   I	   leads	   to	   AKT	   activation	   by	   the	   phosphoinositide-­‐dependent	   kinase-­‐1	  (PDK1)	   and	  mTORC2,	   and	   the	   activated	  AKT	   acts	   on	   tuberous	   sclerosis	   complex	  (TSC1,	   TSC2)	   and	   Rheb,	   leading	   to	   mTORC1	   activation	   that	   causes	   autophagy	  inhibition.	  Hence,	  small-­‐molecule	  inhibitors	  blocking	  both	  PI3K	  and	  mTOR	  would	  have	   the	   advantage	   of	   shutting	   down	   completely	   the	   PI3K/AKT/mTOR	   pathway	  and	  thus	  avoiding	  the	  feedback	  activation,	  seen	  by	  rapamycin	  and	  the	  rapalogues.	  As	   a	   result,	   the	   search	   for	   dual	   PI3K/mTOR	   inhibitors	   blocking	   the	  ATP	   binding	  cleft	  of	  both	  enzymes	  has	  emerged	  as	  an	  interesting	  area	  of	  research.	  	  	  The	   PI3K/AKT	   pathway	   has	   a	   crucial	   role	   in	   controlling	   cellular	   growth	   and	  proliferation	  and	  is	  often	  altered	  in	  cancer.	  Therefore,	  great	  efforts	  have	  been	  done	  to	   find	   potent	   PI3K	   inhibitors	   as	   novel	   agents	   for	   cancer	   treatment.	   The	  development	   of	   dual	   PI3K/mTOR	   inhibitors	   has	   strongly	   benefited	   from	   these	  previous	   studies	   yielding	   interesting	   compound	   classes	   that	  will	   be	   summarized	  below.	  
 PI-­‐103	  and	  derivatives	  Class	   I	   PI3K	   can	   be	   further	   divided	   in	   IA	   (which	   can	   consist	   on	   three	   different	  catalytic	   subunits	   (p110α,	   β	   or	   δ)	   and	   IB	   (p110γ).	   One	   of	   the	   first	   described	  PI3K/mTOR	  dual	  inhibitors,	  PI-­‐103,	  was	  identified	  after	  a	  HTS	  assay	  aimed	  to	  find	  p110α	  inhibitors.	  	  PI-­‐103	   emerged	   initially	   from	   a	   collaboration	   between	   the	   Yamanouchi	  pharmaceutical	   company,	   later	   Astellas,	   and	   the	   group	   of	   Paul	   	  Workman	   at	   the	  Institute	  of	  Cancer	  Research	  (UK).	  The	  screening	  of	  a	  compound	  library	  based	  on	  4-­‐morpholino-­‐2-­‐phenylquinazoline	  and	  related	  analogues	  	  yielded	  the	  scaffold	  1	  as	  initial	   hit.	   Structural	  modification	   of	  1	   resulted	   in	   a	   furan	   analogue	  with	   an	   aryl	  group	  on	   the	  pyrimidine	   ring.	  A	   focused	   library	  based	  on	   this	   improved	   scaffold	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enabled	  the	  identification	  of	  PI-­‐103,	  containing	  a	  morpholino	  pyridofuropirimidine	  core	   and	   bearing	   a	   hydroxyl	   group	   at	   the	   3	   position	   of	   the	   benzene	   ring.21,	   22	  Biological	  evaluation	  of	  PI-­‐103	  confirmed	  low	  nanomolar	  inhibition	  of	  class	  I	  PI3K,	  mTORC1	  and	  mTORC2	  in	  in	  vitro	  studies	  as	  well	  as	  cellular	  activity	  (Figure	  3,	  Table	  1).22,	  23	   	   The	   activity	   of	   PI-­‐103	   as	   autophagy	   inducer	   in	   several	   cancer	   cells	   have	  also	  been	  explored.24	  	  	  	  
	  	  













































	   9	  
	  	  
































2 3 4 5
6
	   10	  
explored	  in	  regard	  to	  cancer	  progression,	  its	  activity	  as	  autophagy	  inducers	  in	  cell	  studies	  has	  been	  initially	  explored	  as	  well.30	  The	  synthetic	  route	  to	  GDC-­‐0980	  is	  shown	  in	  Scheme	  2	  and	  starts	  with	  7	  that	  is	  in	  turn	   prepared	   in	   three	   steps	   from	  methyl-­‐3-­‐amino-­‐2-­‐thiophenecarboxylate.31	  α-­‐Lithiation	  of	  7	  and	  subsequent	  formylation	  with	  DMF	  yielded	  aldehyde	  8	  that	  after	  reductive	   amination	   with	   Boc-­‐piperazine	   followed	   by	   Suzuki	   coupling	   with	   2-­‐aminopyrimidine-­‐4-­‐boronic	   acid	   afforded	   10.	   The	   formation	   of	   the	   final	   amide	  with	  hydroxypropionic	  was	  performed	  in	  the	  last	  step	  after	  Boc	  deprotection	  due	  to	   the	   instability	  of	   this	  group	   to	   the	  high	   temperature	  Suzuki	   reaction	  affording	  GDC-­‐0980.29	  	  
	  
	  
Scheme	   2.	   Reagents	   and	   conditions	   a)	   n-­‐BuLi,	   THF,	   -­‐78	   °C,	   DMF	   -­‐40°C;	   b)	   Boc-­‐piperazine,	   1,2-­‐DCE,	   HC(OCH3)3,	   Na(OAc)3BH,	   96%;	   c)	   2-­‐aminopyrimidine-­‐5-­‐boronic	  acid	  pinacol	  ester,	  Pd(PPh3)2Cl2,	  1	  M	  Na2CO3,	  CH3CN,	  microwave,	  140	  °C,	  15	  min,	  82%;	  d)	  4N	  HCl	  in	  dioxane,	  DCM,	  25°C,	  3	  h,	  100%;	  	  (S)-­‐2-­‐hydroxypropionic	  acid,	   N,N-­‐diisopropylethylamine	   (DIPEA),	   1-­‐[Bis(dimethylamino)methylene]-­‐1H-­‐1,2,3-­‐triazolo[4,5-­‐b]pyridinium	   3-­‐oxid	   hexafluorophosphate	   (HATU),	   DMF,	   25°C,	  30	  min,	  56%.	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BEZ235	  with	  an	  increased	  selectivity	  for	  class	  I	  PI3K	  isoforms,	  and	  also	  activity	  for	  mTOR	   as	   well	   as	   in	   vivo	   antitumor	   activity	   (Table	   1).	   34	   Additional	   studies	   in	  several	  cancer	  cells	  have	  also	  confirmed	  cell	  death	  or	  potent	  growth	  inhibition	  via	  massive	  autophagy	   induction	  by	  BEZ235	  and	   the	  derivative	  BGT226	  even	  at	   low	  nanomolar	  concentrations.35	  The	  specificity	  of	  BEZ235	   for	  PI3K	   in	   front	  of	  PDK1	  was	  revealed	  by	  docking	  studies	  that	  suggested	  an	  electrostatic	  mismatch	  between	  the	  carbonyl	  group	  at	  position	  2	  and	  a	  backbone	  carbonyl	  of	  Leu88	  in	  PDK1	  that	  has	  no	  equivalent	  in	  PI3K.32	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Another	  dual	  mTOR/PI3K	  inhibitors	  is	  XL765	  developed	  by	  Exelixis	  and	  later	  out-­‐licensed	   to	   Sanofi	   (SAR245409).	   XL765	   inhibits	   mTOR	   and	   the	   PI3K	   subunits	  p110α, β, γ and δ	   causing	   cell	   growth	   inhibition	   and	   accumulation	   of	  autophagosomes	   in	   MIAPaCa-­‐2-­‐cells.	   Moreover,	   the	   treatment	   of	   a	   panel	   of	  pancreatic	   cancer	   cells	   with	   XL765	   induced	   enhanced	   apoptotic	   cell	   death	   and	  greater	   autophagy	   induction	   than	   the	   separate	   inhibition	   of	   PI3K	   and	   mTOR	  pathway.38	  Another	  PI3K	  inhibitor	  that	  also	  blocks	  mTOR	  activity,	  albeit	  weakly,	  is	  caffeine	   that	   in	   high	   doses	   enhances	   autophagic	   flux	   acting	   on	   the	  PI3K/mTOR/p70S6	   signalling	   pathway.39	   This	   autophagy	   induction	   would	   be	   in	  agreement	  with	   studies	   showing	   that	   caffeine	   can	   increase	   life	   span	   in	   yeast	   by	  targeting	  mTORC1.40	  Other	  potent	  dual	  mTOR/PI3K	  inhibitors	  have	  been	  recently	  described	   (18)	   although	   their	   activity	   as	   autophagy	   inducers	   has	   not	   been	  explored	  yet	  (Figure	  4).41	  	  
	  	  
Figure	   4.	   	   XL765,	   Caffeine	   and	   the	  pyridopyrimidine	  18	   are	   autophagy	   inducers	  with	  known	  inhibiting	  activity	  of	  the	  kinases	  mTOR	  and	  PI3K.	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with	   unselective	   autophagy	   inhibitors	   have	   shown	   promising	   results	   in	   causing	  apoptosis	  in	  several	  cancer	  cell	  types	  such	  as	  glioma,	  leukaemia.42	  
Pan	  mTOR	  inhibitors	  	  As	  an	  alternative	  strategy	   to	  block	   the	   feed-­‐back	  activation	  of	  AKT,	  a	  second	  and	  more	  potent	  generation	  of	  mTOR	   inhibitors	   targeting	   the	  ATP	  binding	  site	  of	   the	  mTOR	   kinase	   and	   affecting	   both	   protein	   complexes,	   MTORC1	   and	   MTORC2	   has	  been	  developed.14	  Again,	  as	  for	  the	  above	  mentioned	  dual	  PI3K/mTOR	  inhibitors,	  pan-­‐mTOR	   inhibitors	  have	   shown	  promising	   results	   in	   radio	  and	   chemoresistant	  cancer	   cells.	   Autophagy	   is	   a	   cell	   survival	   strategy	   in	   cancer	   cells	   and	   although	  mTOR	   inhibition	   activates	   autophagy,	   it	   seems	   that	   may	   also	   enhance	   their	  sensitivity	   to	   treatment	   by	   triggering	   premature	   senescence.	   The	   mechanism	  controlling	   this	   process	   is	   yet	   under	   investigation	   but	   the	   use	   of	   autophagy	  inducers	   blocking	   mTOR	   activity	   may	   be	   considered	   an	   alternative	   strategy	   for	  cancer	  treatment.43	  	  PP242	  The	   first	   pan-­‐mTOR	   inhibitors	   PP242	   and	   the	   analogue	   PP30,	   were	   initially	  discovered	  by	  the	  group	  of	  Kevan	  M.	  Shokat	   in	  a	  HTS	  assay	  directed	  to	  find	  PI3K	  and	   Ser/Thr	   kinase	   inhibitors.44,	   45	   These	   compounds	   have	   an	   adenine-­‐mimetic	  pyrazolopyrimidine	   scaffold	   and	   selectively	   inhibit	   mTORC1	   and	   mTORC2	   with	  low	   nanomolar	   IC50	   without	   affecting	   other	   kinases	   (Table	   2).	   Moreover	   these	  compounds	  together	  with	   the	  other	  pan-­‐mTOR	  inhibitors	  are	  more	  efficient	   than	  rapamycin	   in	   blocking	   cell	   proliferation	   and	   are	   stronger	   autophagy	   agonist	   in	  several	  cell	  lines.45	  	  	  The	  synthetic	  route	  to	  PP242	  can	  be	  seen	  in	  Scheme	  4	  and	  starts	  upon	  refluxing	  3-­‐amino-­‐4-­‐pyrazolecarbonitrile	   with	   an	   excess	   of	   formamide	   yielding	   the	   4-­‐amino	  substitute	   pyrazolo[3,4-d]pyrimidine	   19.	   Iodation	   using	   N-­‐iodosuccinimide	  followed	  by	  alkylation	  with	  isopropylbromide	  yielded	  intermediate	  20	  that	  after	  a	  Suzuki	   reaction	   with	   5-­‐benzyloxy-­‐1-­‐Boc-­‐indole-­‐2-­‐boronic	   acid	   followed	   by	  debenzylation	  afforded	  the	  final	  compound	  PP242	  (Scheme	  4).44	  The	   X-­‐ray	   co-­‐crystal	   structure	   of	   PP242	  with	  mTOR	   has	   been	   recently	   reported	  indicating	   that	   the	   selectivity	   of	   PP242	   for	   mTOR	   vs	   PI3K	   probably	   relies	   on	   a	  conformational	  change	   involving	  Leucine	  2354	  that	  enables	  the	  hydroxyindole	  of	  PP242	  to	  fill	  a	  deeper	  hydrophobic	  pocket.	  A	  similar	  change	  is	  not	  possible	  in	  PI3K	  due	  to	  the	  replacement	  of	  the,	  leucine	  by	  a	  phenylalanine.25	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Scheme	   4.	   Synthesis	   of	   PP242	   and	   chemical	   structure	   of	   the	   analogue	   PP30.	  Reagents	  and	  conditions:	  a)	  formamide,	  180°C,	  o/n;	  b)	  i)	  NIS,	  DMF	  80°C;	  ii)	  K2CO3,	  DMF,	  80°C,	   isopropylbromide;	   c)	   5-­‐benzyloxy-­‐1-­‐boc-­‐indole-­‐2-­‐boronic	   acid,	   EtOH-­‐DME,	  Pd(PPh3)4	  saturated	  Na2CO3,	  80°C	  ;	  d)	  formic	  acid,	  HCl.	  
 Torin	  
	  Another	  potent	  mTOR	  inhibitor	  that	  has	  been	  widely	  used	  as	  autophagy	  inducer	  	  is	  	  Torin,	   developed	   by	   the	   group	   of	   Nathaniel	   S.	   Gray	   after	   the	   screening	   of	   a	  compound	   library	   that	  provided	  quinolone-­‐based	  hits	  with	  moderate	   activity	   for	  mTOR	   (5	   µM)	   and	   selectivity	   against	   PI3K	   (Scheme	   5).	   A	   medicinal	   chemistry	  approach	   based	   on	   an	   iterative	   process	   of	   chemical	   modification	   and	   biological	  evaluation	   was	   then	   applied	   yielding	   more	   potent	   and	   selective	   compounds.	  Briefly,	  varying	  the	  side	  chains	  at	  4-­‐	  and	  6-­‐positions	  of	  the	  quinoline	  did	  not	  result	  in	  active	  cellular	  compounds.	  However	  when	   these	  changes	  were	  combined	  with	  the	   introduction	   of	   a	   six-­‐membered	   lactam	   resulted	   in	   Torin,	   a	   tricyclic	  benzonaphthridinone	   scaffold	   which	   inhibited	   mTORC1	   and	   MTORC2	   at	   pM	  concentrations	   in	   vitro	   and	   showing	   a	   1000	   fold	   improved	   mTOR	   celluar	  potency.46	  Moreover,	  Torin,	  presented	  a	  good	  selectivity	  profile	  with	  a	  1000-­‐fold	  selectivity	  over	  PI3K	  and	  a	  100-­‐fold	  selectivity	  to	  450	  other	  protein	  kinases	  when	  screened	  at	  10	  µM	  concentration.47	  Torin	  together	  with	  PP242	  	  (both	  tested	  at	   	  1	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Scheme	   6.	   Synthesis	   of	   Torin2.	   Reagents	   and	   conditions:	   a)	   3-­‐(trifluoromethyl)aniline,	   1,4-­‐dioxane,	   90	   °C,	   4-­‐12h;	   b)	   NaBH4,	   EtOH,	   rt,	   4h;	   c)	   i)	  MnO2,	   CH2Cl2,	   rt,	   6h;	   ii)	   triethylphosphonoacetate,	   K2CO3,	   EtOH,	   100°C,	   12h;	   d)	  PdCl2(PPh3)2,	  	  Na2CO3,	  1,4-­‐dioxane,	  100°C,	  12h.	  	  	  	  	  	  	  The	   co-­‐crystal	   structure	   of	   Torin2	   with	   mTOR	   revealed	   the	   mode	   of	   binding,	  confirmed	  some	  of	  the	  predicted	  hydrogen	  bonds	  and	  showed	  extensive	  stacking	  of	   the	   tricyclic	   benzonaphthyridinone	   ring	  with	   the	   indole	   group	   of	   Tryptophan	  (Trp)	   2239.	   Apart	   from	   contributing	   to	   the	   low	   nM	   potency	   of	   Torin2	   this	  interaction	  may	  also	  have	  a	  role	  in	  the	  specificity	  over	  PI3K,	  because	  Trp	  2239	  is	  not	  present	  in	  canonical	  protein	  kinases	  or	  in	  PI3K.25	  Ku-­‐0063794	  Another	   ATP-­‐competitive	   inhibitor	   of	   mTORC1	   and	   mTORC2	   is	   Ku-­‐0063794,	  developed	  by	  Astra	  Zeneca	  after	  a	  HTS	  assay	  that	  yielded	  the	  racemate	  29	  as	  initial	  hit.	   The	   replacement	   of	   the	   piperidine	   by	   a	   substituted	  morpholine	   reduced	   the	  overall	  lipophilicity	  and	  increased	  the	  activity.	  Further	  optimization	  was	  suggested	  by	   docking	   studies	   using	   an	   homology	   model	   of	   mTOR	   that	   indicated	   that	   the	  substitution	  of	  the	  pyridopyrimidine	  at	  the	  C7	  position	  would	  provide	  compounds	  able	  to	  access	  additional	  pockets	  in	  the	  ATP	  binding	  site.	  Indeed,	  the	  incorporation	  of	   electron-­‐donating	   substituents	   in	   the	   para	   position	   combined	   with	   hydrogen	  bond	  donors	  in	  the	  meta	  position	  resulted	  in	  Ku-­‐0063794	  with	  a	   low	  nM	  IC50	  for	  mTORC1	   and	   mTORC2	   and	   good	   selectivity	   over	   other	   76	   kinases	   and	   7	   lipid	  kinases.51	  With	   the	  aim	  of	   increasing	   the	  aqueous	  solubility	  and	  decreasing	  side-­‐target	  activity,	  two	  additional	  derivatives	  were	  prepared,	  AZD8055	  and	  AZD2014	  which	  display	  autophagy	   induction	   in	  cells52	  and	  are	  currently	   in	  phase	   I	   clinical	  studies	  (Figure	  5).	  53	  The	  effect	  of	  AZD8055	  in	  neurological	  disorders	  has	  also	  been	  investigated.	  Hence,	  AZD8055	  has	  shown	  to	  be	  a	  potent	  autophagy	  inducer	  with	  a	  EC50	   of	   180	   nM	   and	   to	   cause	   an	   increased	   degradation	   of	   mutant	   huntingtin	  aggregates	   in	   a	   neuronal	   cell	   model	   of	   this	   neurodegenerative	   disease.	   Other	  mTOR	  inhibitors	  such	  as	  BEZ235	  or	  BKM124	  were	  also	  active	  in	  this	  assay	  while	  the	  rapamycin	  analogue	  everolimus	  fail	  to	  show	  any	  effect.54	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Figure	  6.	  mTOR	  inhibitor	  X-­‐387	  and	  AKT	  inhibitors	  Perifosine,	  MG-­‐2477	  and	  10-­‐NCP	  	  	  In	  summary,	  pan	  mTOR	  inhibitors	  have	  shown	  potent	  effects	  on	  mTOR	  signalling	  pathway	   compared	   to	   the	   weak	   rapamycin.	   Moreover,	   their	   anticancer	   effect	   is	  usually	   superior	   due	   to	   the	   concomitant	   inhibition	   of	   rapamycin-­‐insensitive	  mTORC2	  activity	  in	  addition	  to	  mTORC1	  inhibition.	  	  Although	  the	  current	  interest	  in	   the	   development	   of	   mTOR	   inhibitors	   is	   mainly	   focused	   on	   cancer	   treatment,	  their	  use	  as	  autophagy	  inducers	  in	  research	  or	  with	  therapeutic	  aims,	  such	  as	  the	  treatment	  of	  neurological	  disorders,	  is	  increasing.	  However,	  apart	  from	  regulating	  autophagy,	  the	  mTOR	  signalling	  also	  controls	  several	  other	  cellular	  processes	  such	  as	  protein	  synthesis	   	  and	  consequently,	  mTOR	   inhibition	  may	  be	   important	  side-­‐effects	  that	  should	  be	  also	  considered,.	  	  
Table	   2.	   Activities	   (IC50,	   nM)	   of	   the	   reported	   pan-­‐mTOR	   inhibitors.	   a)	   kinase	   in	  vitro	  data	  was	  obtained	  with	  precipitated	  proteins;	  b)	  mTOR	   inhibition	  data	  was	  obtained	  in	  vitro	  assay;	  c)	  Cellular	  mTOR	  inhibition	  data	  obtained	  using	  a	  Förster	  resonance	   energy	   transfer	   (FRET)-­‐based	   by	   monitoring	   the	   phosphorylation	   of	  S6K1	  using	  a	  phospho	  specific	  antibody.	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Chemical	  compounds	  can	  also	   indirectly	  affect	  mTOR	  signaling	  and	  consequently	  autophagy	   by	   acting	   on	   upstream	   targets	   suchs	   as	   AMPK	   (Adenosine	  MonoPhosphate-­‐activated	   protein	   kinase),	   tuberous	   sclerosis	   2	   	   (TSC)	   or	   the	  kinase	  AKT.	  mTOR	  is	  a	  target	  for	  AKT,	  therefore	  AKT	  inhibition	  supresses	  mTOR	  activation	  that	  	  also	  results	  in	  autophagy	  induction.	  	  As	  a	  result,	  several	  AKT	  inhibitors	  have	  been	  reported	  as	  autophagy	  modulators	  and	  will	  be	  summarized	  below.	  	  Perifosine	   is	   an	   alkylphospholipid	   that	   induces	   autophagy	   via	   AKT	   inhibition,58	  although	  additional	  studies	  have	  suggested	  that	  this	  effect	  may	  be	  facilitated	  by	  the	  degradation	  of	  major	  components	  of	   the	  mTOR	  complex,	   including	  mTOR,	  raptor	  and	   rictor.59	   The	   tubulin	   polymerization	   inhibitor	   MG-­‐2477	   was	   also	   shown	   to	  induce	   protective	   autophagy	   in	   A549	   cells	   probably	   due	   to	   blockage	   of	   AKT.60	  Another	  known	  AKT	  inhibitor	  with	  activity	  as	  autophagy	  inducer	  in	  neuronal	  cells	  is	   the	   N-­‐substituted	   phenoxazine	   10-­‐NCP	   (Figure	   6).61	   Some	   related	   compounds	  such	  as	  trifluoroperazine,	  promazine,	  chlorpromazine	  or	  trifluoropromazine,	  have	  showed	   also	   similar	   effect.	   However,	   additional	   studies	   showed	   that	   these	  compounds	  may	  act	   in	  a	  AKT-­‐	  and	  mTOR-­‐independent	  manner	  and	  therefore	  the	  exact	  mechanism	  of	  action	  is	  unknown	  yet.62	  As	  example,	  trifluoroperazine	  is	  also	  a	   known	   calmodulin	   inhibitor	   and	   may	   exert	   its	   function	   through	   the	   Ca2+-­‐signalling	  pathway.63	  	  	  
AMPK	  activators	  AMPK	   (Adenosine	   MonoPhosphate-­‐activated	   protein	   kinase)	   induces	   autophagy	  by	  targeting	  mTORC1	  or	  tuberous	  sclerosis	  2	  or	  by	  direct	  phosphorylation	  of	  Ulk	  (the	  Agt1/Ulk	  complex	  is	  located	  at	  the	  initial	  isolation	  membrane	  and	  required	  for	  autophagosome	   formation).64	   Hence,	   several	   AMPK	   activators	   have	   also	   been	  reported	  as	  autophagy	  inducers.	  	  The	  antidiabetic	  drug	  metformin	  is	  one	  of	  the	  AMPK	  activators	  widely	  used	  autophagy	  inducer.65	  Moreover,	  metformin	  can	  also	  extend	  life	  span	  in	  mice.66	  However,	  recent	  results	  suggest	  that	  metformin	  may	  inhibit	  mTOR-­‐signalling	  by	  processes	  that	  do	  not	  depend	  on	  AMPK	  (Figure	  7).67	  The	  natural	  product	  Rottlerin,	  isolated	  from	  Mallotus	  philippinensis,	  can	  be	  also	  included	  in	  this	  category.	  Although	  Rottlerin	  	  is	  	  as	  protein	  kinase	  C	  delta	  inhibitor,	  	  it	  can	  also	  induce	  autophagy	  in	  a	  PKC-­‐independent	  manner68,	  69	  probably	  through	  AMPK	  activation	  and	  proteasome	  inhibition.70	  Previous	  studies	  have	  also	  shown	  the	  activity	  of	  Rottlerin	  as	  well	  as	  known	  drugs	  such	  as	  Niclosamide,	  Amiodarone	  and	  Perhexiline	  in	  autophagy	  induction	  suggesting	  their	  implication	  as	  mTOR-­‐signalling	  inhibitors.68	  More	  recently,	  additional	  studies	  have	  suggested	  that	  Niclosamide	  (10	  mM)	  acts	  as	  a	  protonophore	  and	  its	  selective	  effect	  on	  mTORC1	  is	  caused	  by	  the	  acidification	  of	  the	  cytoplasm	  acidification	  rather	  than	  by	  the	  direct	  inhibition	  of	  the	  mTORC1.71	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Figure	   7.	   Structures	   of	   autophagy	   inducers	   suggested	   to	   act	   on	   AMPK	   and	   the	  protonophore	  	  Niclosamide.	  	  
Miscellaneous.	  Due	   to	   the	   crucial	   role	   of	   the	   mTOR-­‐signalling	   cascade	   in	   the	   regulation	   of	  autophagy,	   when	   autophagy	   inducers	   with	   unknown	   target	   are	   identified,	   the	  implication	   of	   the	   mTOR	   network	   is	   usually	   investigated	   in	   order	   to	   discard	   or	  confirm	  its	  involvement.	  As	  a	  result,	  some	  autophagy	  inducers	  have	  been	  proven	  to	  function	  through	  the	  mTOR	  pathway	  albeit	  with	  a	  yet	  unknown	  target.	  This	  is	  the	  case	   of	   several	   Farnesyltransferase	   Inhibitors	   (FTI),72	   Δ9-­‐tetrahydrocannabinol73	  and	   phenethylisothiocyanate	   (PEITC).74	   The	   related	   benzyl	   ITC	   also	   promotes	  autophagy	   induction	   in	   an	   mTOR-­‐depending	   manner	   with	   a	   yet	   unknown	  mechanism	  of	  action.75	  Another	  example	  is	  compound	  C,	  also	  called	  Dorsomorphin,	  an	   AMPK	   inhibitor	   that	   also	   functions	   as	   autophagy	   inducer.	   However,	   its	  mechanism	   of	   action	   is	   probably	   AMPK-­‐independent	   and	   mediated	   by	   AKT	  suppression	  and	  subsequent	  downregulation	  of	  mTOR-­‐signalling	  (Figure	  8).	  76	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aminopyrimidones	  SMER10	  and	  SMER10a	   lacking	  the	  amino	  group	  at	  3	  position,	  the	   vinylogous	   amide	   SMER18	   and	   the	   bromo-­‐substituted	   quinazoline	   SMER28,	  	  obtained	  by	  microwave-­‐assisted	  alkylation	  of	  4-­‐chloroquinzaoline	  with	  allylamine	  (Figure	  9).	  The	  exact	  mechanism	  of	  action	  of	  the	  SMER	  compounds	  is	  not	  clear	  yet.	  The	  available	  data	  suggest	  that	  they	  act	  in	  a	  mTOR-­‐independent	  fashion,	  although	  they	   may	   also	   act	   on	   a	   yet	   unknown	   component	   of	   the	   mTOR	   pathway.	  	  	  Independently	  of	   their	  mechanism	  of	  action,	   these	  scaffolds	  may	  serve	  as	  a	  good	  starting	  point	  for	  the	  synthesis	  of	  more	  potent	  and	  selective	  autophagy	  inducers.77	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Scheme	   7.	   Structure	   of	   STF-­‐62247	   and	   Englerin	   A;	   Reagents	   and	   conditions:	   a)	  Br2,	  30%	  HOAc/HBr,	  -­‐40C	  1h,	  -­‐75°C	  1h;	  b)	  NH4SCN,	  m-­‐toluidine	  in	  1M	  HCl	  100°C,	  16h;	   or	  Benzoyl	   chloride,	  NH4SCN,	   acetone,	   	   15	  min,	   reflux;	  m-­‐toluidine,	   30	  min,	  reflux;	  then	  aqueous	  NaOH	  (10	  %	  w/v);	  c)	  EtOH,	  reflux,	  1h.	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also	  been	  implicated	  in	  autophagy	  regulation.94	  This	  is	  the	  case	  of	  2-­‐hydroxyoleic	  acid,	   which	   has	   been	   proven	   to	   induce	   autophagic	   cell	   death	   in	   human	   glioma	  cells.95	  	  
	  
 	  
Figure	   10.	   Chemical	   structures	   of	   additional	   autophagy	   inducers.	   Some	   of	   these	  compounds	  have	  been	  suggested	  to	  act	  via	  generation	  of	  reactive	  oxygen	  species	  (ROS).	  	  In	   summary,	   important	   efforts	   have	   been	  done	   for	   the	   identification	   of	   chemical	  tools	  modulating	   autophagy	   acting	   directly	   or	   indirectly	   on	   the	  mTOR	   pathway.	  Although	   most	   of	   the	   described	   compounds	   are	   mainly	   useful	   tools	   for	   basic	  research,	   their	   activity	   in	   several	   disease	   is	   also	   being	   investigated.5	   However,	  apart	   from	   their	   effect	   on	   autophagy	   most	   of	   these	   compounds	   have	   additional	  cellular	   effects.	   Consequently,	   there	   is	   still	   a	   strong	  need	   for	   the	  development	  of	  more	  selective	  autophagy	  inducers.	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type	   Ca2+	   channel	   blockers	   such	   as	   verapamil,	   loperamide,	   nimodipine,	  nitrendipine	  and	  amiodarone	  and	  calpain	  inhibitors	  such	  as	  calpastatin	  have	  been	  also	  described	  as	  autophagy	  inducers	  (Figure	  11).97	  Additional	  autophagy	  inducers	  acting	   on	   calcium	   signalling	   have	   emerged	   from	   HTS	   assays.	   As	   example,	  fluspirilene,	   trifluoperazine,	   a	   known	   calmodulin	   inhibitor,63	   pimozide,	  niguldipine,	   nicardipine,	   and	   penitrem	   A	   were	   identified	   from	   a	   480	   compound	  library	  employing	  a	  HT	  image-­‐based	  screening	  assay	   followed	  by	  a	  cellular	  assay	  to	  measure	  protein	  degradation.	  Although	  these	  identified	  drugs	  are	  indicated	  for	  different	  diseases	  they	  all	  share	  a	  common	  activity	  as	  calcium	  signalling	  blockers.98	  	  	   	  
	  
 
Figure	  11.	  mTOR-­‐independent	  inducers	  of	  autophagy.	  
 A	   screening	   of	   FDA	   approved	   drugs	   to	   search	   for	   autophagy	   inducers	   revealed	  Rilmenidine,	   an	   hypertensive	   agents	   that	   acts	   on	   imidazoline	   receptors	   and	   also	  reduces	  cAMP	  levels.	  This	  compound	  showed	  promising	  results	  in	  a	  mouse	  model	  of	   the	   neurodegenerative	   Huntington	   disease	   and	   its	   effect	   is	   currently	   being	  investigated	  in	  clinical	  trials.97,	  99	  
 








































	   25	  
result	   in	  selective	  activators	  of	  CMA	  without	  affecting	  other	  autophagy	  pathways.	  To	  this	  end,	  a	  small	  library	  of	  29	  compounds	  based	  on	  retinoic	  acid	  derivatives	  was	  designed	  and	  synthesized.	  Modifications	  at	  the	  C4	  position	  at	  the	  hydrophobic	  ring	  were	   incorporated	   to	   prevent	   its	   oxidation.	   Derivatives	   were	   grouped	   in	   four	  major	   families:	   aminonitrile	   retinoids	   (AmR),	   boron-­‐aminonitrile	   retinoids	  (BAmR),	   guanidine	   retinoids	   (GR)	   and	   atypical	   retinoics	   (AR)	   (Figure	   12).	   After	  toxicity	  and	  cellular	  studies,	  three	  compounds	  (AR7,	  GR1	  and	  GR2)	  were	  identified	  as	   inducers	   of	   CMA,	   thus	   confirming	   that	   the	   selective	   activation	   of	   CMA	   can	   be	  achieved	  by	  retinoic	  acid	  derivatives	  and	  showing	  the	  potential	  selective	  targeting	  of	  autophagy	  processes	  using	  small-­‐molecules.	  	   	  
	  	  
Figure	  12.	  ATRA	  and	  ATRA	  derivatives	  have	  been	  tested	  for	  their	  activity	  as	  RARα	  receptor	  antagonists	  and	  as	  inducers	  of	  chaperone-­‐mediated	  autophagy.	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  There	  are	  several	  possible	  regulation	  steps	  on	  autophagy	  and	  have	  been	  therefore	  considered	  as	  possible	  targets	  to	  inhibit	  this	  process.	  The	  best-­‐characterized	  ones	  are	   the	   lipid	  kinases	  PI3K.	   	  The	   formation	  of	   the	   initial	  phagophore	   requires	   the	  presence	   of	   phosphatidylinositol-­‐3-­‐phosphate	   (PI3P)	   and	   therefore,	   PI3K	  
inhibitors	   blocking	   the	   generation	   of	   this	   phosphorylated	   lipid	   can	   function	   as	  autophagy	  inhibitors.	  	  
	  
PI3K	  Inhibition	  As	  mentioned	  above,	  the	  kinases	  PI3K	  have	  different	  roles	  in	  autophagy	  regulation.	  	  Class	   I	   PI3K	   negatively	   regulates	   this	   process	   and	   consequently,	   class	   I	   PI3K	  inhibitors	  are	  autophagy	  inducers.	  However,	  class	  III	  PI3K	  is	  a	  positive	  regulator	  of	  autophagy	   with	   a	   crucial	   role	   in	   autophagosome	   cargo	   sequestration	   and	  therefore,	  class	  III	  PI3K	  inhibitors	  cause	  an	  inhibition	  of	  autophagy.	  Since	  class	  III	  is	  downstream	  of	  class	  I,	  unspecific	  or	  general	  PI3K	  inhibitors	  have	  as	  a	  final	  effect	  the	  inhibition	  of	  autophagy.	  Remarkable	  examples	  of	  this	  activity	  class	  compounds	  are	  3-­‐methyladeninde,	  wortmannin	  and	  LY294002	  (Figure	  13).103	  	  Wortmannin	  is	  a	  natural	  product	  that	  irreversibly	  blocks	  PI3K	  upon	  formation	  of	  an	   enamine	   at	   C20	   with	   a	   Lys	   residue	   of	   the	   protein.104,	   105	   LY294002,	   a	  morpholino-­‐derivative	  of	  quercetin,	   is	   a	   synthetic	  pan	  PI3K	   inhibitors	  developed	  by	   Lilly	   that	   blocks	   all	   the	   kinase	   classes	   but	   requires	   high	   concentrations.	  Although	   is	   500	   times	   less	   potent	   than	   Wortmannin,	   its	   improved	   chemical	  stability	  has	  promoted	   its	  wide	  use.	  X-­‐ray	   co-­‐crystal	   structure	  of	  LY294002	  with	  PI3Kγ	  has	  been	  elucidated	  showing	  that	  the	  interaction	  relies	  on	  a	  hydrogen	  bond	  	  between	   the	  morpholino	   oxygen	   and	   the	   backbone	   amide	   of	   Val	   882.104	   Neither	  Wortmannin	   nor	   LY294002	   have	   progressed	   to	   clinical	   trials	   due	   to	   their	   poor	  pharmacokinetic	   properties	   and	   high	   toxicity	   although	   they	   have	   been	   widely	  employed	   as	   tools	   in	   basic	   research.	   However,	   special	   caution	   should	   be	   taken	  when	  using	  these	  unspecific	  PI3K	  inhibitors,	  because	  due	  to	  the	  similarity	  of	  PI3K	  with	   mTOR,	   they	   also	   inhibit	   mTOR	   signalling	   or	   other	   kinases	   giving	   in	   some	  cases	   confusing	   outputs.106	   More	   recently	   SF-­‐1126	   (Semafore),	   a	   prodrug	   of	  LY294002	   conjugated	   to	   a	   tetrapeptide	   (RGDS,	   that	   stands	   for	   Arginine-­‐glycine-­‐aspartic	   acid-­‐serine),	   has	   been	  described.	   This	   peptide	   is	   a	   known	  binding	  motif	  for	  integrin	  located	  in	  the	  tumour	  vasculature.	  The	  conjugated	  SF-­‐1126	  is	  directed	  to	  this	  region	  and	  once	  there	  specifically	  inhibits	  PI3K-­‐dependent	  angiogenesis	  in	  the	   tumour.107	   Another	   general	   PI3K	   inhibitor	   widely	   employed	   as	   autophagy	  inhibitor	   in	   basic	   research	   is	   3-­‐methyladenine	   (3-­‐MA).	   Although	   3-­‐MA	   inhibits	  both	   class	   I	   and	   class	   II	   PI3K,	   at	   the	   10	   mM	   concentration	   typically	   used	   for	  inhibiting	  autophagy	  it	  has	  preferentially	  for	  class	  III	  PI3K.	  However	  its	  dual	  effect	  may	   cause	   complicated	   outputs	   as	   3-­‐MA	   inhibits	   permanently	   class	   I	   and	   only	  transiently	  class	  III	  that	  after	  long	  treatment	  causes	  autophagy	  induction	  instead	  of	  inhibition.108	  Although	  class	  III	  inhibitors	  are	  widely	  used	  as	  autophagy	  inhibitors	  one	  should	  take	  into	  account	  that	  apart	  from	  the	  poor	  selectivity	  of	  the	  mentioned	  inhibitors,	   as	   PI3K,	   both	   class	   I	   and	   class	   III,	   regulate	   several	   cell	   signalling	   and	  membrane	   trafficking	   processes,	   these	   are	   not	   specific	   autophagy	   inhibitors	   and	  many	   other	   cellular	   processes	   may	   be	   also	   affected.	   Hence,	   until	   more	   specific	  modulators	  are	  found,	  results	  obtained	  using	  these	  compounds	  should	  be	  carefully	  taken	  and	  validated	  using	  genetic	  approaches.	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potassium	  carbonate	  	  yielded	  MHY1485	  with	  a	  overall	  yield	  of	  48%.117	  	  	  
	  
Scheme	   9.	   Reagents	   and	   conditions:	   triethylamine,	   acetone	   -­‐10°C,	   1h;	   4-­‐nitroaniline,	  K2CO3,	  DMF,	  4h	  reflux.	  	  




























	   30	  
	  
Figure	  14.	  Correct	  localization	  and	  function	  of	  LC3	  is	  crucial	  for	  the	  regulation	  of	  autophagy.	   LC3	   needs	   to	   be	   associated	   to	   the	   autophagosome	   membrane	   to	   be	  active	   and	   this	   is	  mediated	   by	   C-­‐terminal	   lipidation	  with	   a	   PE	   unit	  mediated	   by	  several	  Atg	  proteins.	  	  Some	   preliminary	   attempts	   to	   find	   selective	   inhibitors	   for	   Atg4	   have	   been	  described.	  The	   first	   inhibitors	  have	  been	   identified	  upon	  screening	  of	   the	  LOPAC	  (Library	  of	  Pharmacologically	  Active	  Compounds)	  library	  and	  a	  compound	  library	  from	  Spectrum	  resulting	   in	   the	   identification	  of	   three	  compounds	   inhibiting	  Atg4	  with	  µM	  activity	   (Figure	  15).120	  Additionally,	  Atg4	  has	  also	  been	  suggested	   to	  be	  the	  target	  of	  reactive	  oxygen	  species	  that	  would	  act	  by	  modifying	  and	  inhibiting	  its	  catalytic	  cysteine.51	  Apart	   from	   this	   crucial	   role	   in	   autophagosome	   elongation,	   LC3	   and	   the	   yeast	  homolog	   Atg8	   are	   also	   involved	   in	   the	   recruitment	   of	   specific	   cargo	   to	   the	  phagophore	  in	  a	  process	  known	  as	  selective	  autophagy.121	  This	  is	  done	  via	  an	  LC3-­‐interacting	   region	   (LIR)	   motif	   present	   in	   proteins.	   	   The	   LIR	   motif	   is	   a	  W/F/YxxL/I/V	   sequence	   preceded	   by	   negatively-­‐charged	   residues.	   The	   aromatic	  amino	   acids	   (W/F/Y)	   can	   be	   a	   tryptophan,	   phenylalanine	   or	   tyrosine	   residues,	  while	   the	   aliphatic	   amino	   acids	   (L/I/V)	   can	   be	   leucine,	   isoleucine	   or	   valine	  residues	  and	  X	  is	  any	  other	  amino	  acid.122	  	  Apart	  from	  this	  role	  in	  the	  sequestration	  of	  the	  cargo,	  several	  proteins	  belonging	  to	  the	  autophagy	  machinery,	  such	  as	  Atg3	  or	   Atg13,	   also	   possess	   a	   LIR	   motif,	   that	   enables	   its	   correct	   localization	   in	   the	  phagophore	   upon	   LC3	   interaction.	   Preliminary	   attempts	   suggest	   that	   these	  Atg8/LC3	  	  interactions	  with	  LIR-­‐containing	  proteins	  can	  be	  investigated	  as	  druggable	  targets.	  Recently,	   small	   molecule	   inhibitors	   of	   the	   Plasmodium	   falciparum	   Atg8-­‐Atg3	  interaction	  have	  been	  described	  upon	  screening	  of	  a	  library	  containing	  352	  small	  fragments.	   This	   screening	   led	   to	   the	   identification	   of	   pyrogallol	   (1,2,3-­‐trihydroxybenzene)	  that	  inhibits	  the	  Atg8-­‐Atg3	  interaction	  with	  an	  IC50	  of	  150	  µM	  (Figure	  15).123	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Figure	  15.	  Small	  molecules	  inhibitors	  of	  Atg4	  and	  Atg8-­‐Atg3	  interaction	  identified	  in	  HTS	  assays.	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separately	  but	   it	   is	  usually	  recommended	  to	  use	  them	  in	  combination	  in	  order	  to	  achieve	  a	  complete	  blockage	  of	  lysosomal	  degradation	  (E64d,	  pepstatin	  10	  µg/ml,	  Leupeptin	  1	  µg/ml).	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Figure	  17.	  Inhibitors	  of	  autophagy	  that	  modify	  the	  lysosomal	  pH.	  	  Neutralization	   of	   lysosomal	   pH	   can	   also	   be	   achieved	   with	   lysosomotropic	  compounds,	  weak	  bases	  that	  preferentially	  accumulate	  in	  the	  lysosomes	  by	  an	  ion	  trapping	  mechanism.	  Weak	  bases	  may	  be	  partially	  deprotonated	  at	  phsysiological	  pH	   and	   the	   resulting	   deprotonated	   form	   is	  more	  membrane	   permeable	   than	   the	  protonated	  form.	  Once	  inside	  the	  lysosome,	  it	  gets	  protonated	  and	  thus	  trapped	  in	  this	  organelle.	  This	  protonation	  step	  causes	  a	  neutralization	  of	  lysosomal	  pH	  which	  leads	  to	  the	  inhibition	  of	  lysosomal	  enzymes	  that	  require	  acidic	  pH	  for	  its	  correct	  function	  and	   subsequently	   to	   inhibition	  of	   lysosomal	  protein	  degradation.130	  The	  antimalaria	   Chloroquine	   (usually	   used	   at	   50	   µm	   concentration),	  hydroxychloroquine	  and	  propylamine	  are	  the	  classical	  examples	  of	  this	  compound	  class,	  however	   these	   inhibitors	  need	   to	  be	  carefully	  used	  as	   they	  have	  additional	  effects	  such	  as	  the	  blocking	  of	  ATP	  production.	  Moreover,	  any	  treatment	  affecting	  lysosomal	   function	   can	   also	   affect	   other	   cellular	   processes	   such	   as	   endocytosis.	  Hence,	  caution	  should	  be	  taken	  with	  results	  obtained	  using	  this	  type	  of	  inhibitors.	  Due	  to	  the	  lack	  of	  more	  specific	  inhibitors	  and	  despite	  its	  unspecific	  effect	  and	  the	  possible	   associated	   toxicity,	   this	   compound	   class	   has	   been	   widely	   used	   in	   basic	  research	  to	  block	  autophagy.	  Moreover,	  the	  first	  clinical	  trials	  based	  on	  autophagy	  inhibition	  are	  also	  focused	  on	  the	  use	  of	  these	  compounds.	  Thus,	  chloroquine	  and	  hydroxichloroquine	   are	   currently	   being	   investigated,	   together	   with	   several	  chemotherapeutic	   agents,	   in	   several	   ongoing	   phase	   I	   and	   phase	   II	   clinical	   trials	  aimed	  to	  explore	  if	  the	  outcome	  in	  cancer	  therapy	  can	  be	  improved	  via	  autophagy	  inhibition.131	  However,	  recent	  studies	  have	  also	  suggested	  that	  chloroquine	  effect	  on	  cancer	  may	  be	  independent	  on	  autophagy	  induction.132	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implications	   in	   several	   relevant	   processes	   such	   as	   neurodegenerative	   diseases,	  cancer,	  and	  age-­‐related	  disorders.	  As	  a	  result,	  the	  search	  for	  small-­‐molecules	  able	  to	  inhibit	  or	  induce	  autophagy	  is	  an	  emerging	  area	  of	  research.6	  	  Despite	  these	  great	  advances	  seen	  in	  the	  last	  years,	  most	  of	  the	  existing	  autophagy	  modulators	   act	   still	   in	   a	   non-­‐specific	  manner.	   Hence,	   potent	   autophagy	   inducers	  inhibiting	   the	   lipid	   kinase	   PI3K	   and/or	   the	   Ser/Thr	   mTOR	   kinase	   have	   been	  identified.	   These	   compounds	   overcome	   the	   limitations	   of	   rapamycin	   but	   still	  modulate	  many	  cellular	  processes	   in	  addition	  to	  autophagy.	  Analogously,	  most	  of	  known	   autophagy	   inducers	   are	   still	   inhibitors	   of	   lysosomal	   function.	   However,	  important	   preliminary	   work	   has	   already	   been	   done	   in	   the	   search	   of	   small-­‐molecules	   able	   to	   specifically	   modulate	   autophagy.	   Hence,	   the	   structural	  characterization	  of	  important	  autophagy	  regulators	  such	  as	  the	  lipid	  kinase	  Vps34	  have	  enabled	  the	  synthesis	  of	  compounds	  that	  may	  serve	  as	  a	  basis	  for	  obtaining	  selective	   inhibitors	   of	   autophagy.	   Moreover,	   the	   discovery	   a	   decade	   ago	   of	   the	  autophagy	  machinery	  (Atg	  proteins)	  has	  also	  paved	  the	  way	  for	  the	  identification	  of	  novel	  targets	  that	  will	  be	  probably	  employed	  in	  a	  near	  future	  to	  obtain	  specific	  autophagy	  modulators.	  Despite	   all	   these	   efforts,	   the	   identification	   of	   novel	   specific	   autophagy	   targets	   as	  well	   as	   the	   development	   of	   selective	   modulators	   of	   the	   known	   ones	   is	   still	   a	  challenging	   and	   demanding	   project.	   Many	   lines	   of	   research	   can	   be	   applied	   to	  achieve	  these	  goals.	  One	  approach	  is	  the	  better	  characterization	  of	  known	  targets	  facilitating	  the	  rational	  design	  of	  inhibitors	  as	  illustrated	  by	  the	  advances	  observed	  with	   the	   Vps34	   kinase.	   Another	   strategy	  will	   be	   the	   development	   of	   HTS	   assays	  focused	  on	  specific	  autophagy	  targets.	  These	  approaches	  will	  be	  probably	  focused	  on	  the	  members	  of	  autophagy	  machinery	  and	  will	  require	  a	  prior	  characterization	  of	   the	   proteins	   involved	   in	   this	   process	   as	   well	   as	   their	   interactions	   with	   other	  proteins	   (i.e.	   Atg8-­‐Atg3).	   	   Finally,	   the	   identification	   of	   novel	   targets	   and	  modulators	  by	  the	  combination	  of	  phenotypic	  assays,	  HTS	  of	  chemical	  libraries	  and	  proteomics	   studies	   it	   is	   also	   expected	   and	   will	   strongly	   contribute	   to	   a	   better	  knowledge	   in	  autophagy	  research.	   	   Independently	  of	   the	  strategy	   followed,	   these	  efforts	  will	  not	  be	  successful	  without	  the	  involvement	  of	  the	  chemical	  community.	  The	  work	  described	  in	  this	  report	  summarizes	  the	  recent	  efforts	  made	  by	  chemists	  and	  biologist	  in	  the	  development	  of	  small-­‐molecules	  modulators	  of	  autophagy.	  The	  continuation	  of	  this	  long-­‐term	  collaboration	  will	  be	  of	  particular	  importance	  in	  this	  promising	   research	   field	   and	  will	   definitely	   contribute	   to	   achieve	   these	   expected	  goals.	  Acknowledgements	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